Perspective Therapeutics Announced Updated Interim Results From Its Ongoing Phase 1/2a Trial Of [212Pb]VMT-α-NET In Unresectable Or Metastatic Somatostatin Receptor Type 2 Expressing Neuroendocrine Tumors
Benzinga Newsdesk 10 months ago
BiotechHealth CareGeneral
Updated interim results with an additional ~13 weeks of follow-up since the prior update[212Pb]VMT-α-NET continues to be well-toleratedUpdated efficacy analysis suggests durable disease control and deepening of tumor
- Updated interim results with an additional ~13 weeks of follow-up since the prior update
- [212Pb]VMT-α-NET continues to be well-tolerated
- Updated efficacy analysis suggests durable disease control and deepening of tumor response per RECIST v1.1 in the first 23 patients in Cohort 2 and both patients in Cohort 1
- Objective response in 39% of patients in Cohort 2 regardless of SSTR2 expression profile, including one Cohort 2 patient who experienced an initial objective response pending confirmation since the prior update, and 8 previously reported confirmed responders
- Cohort 3 (6.0 mCi) dose limiting toxicities (DLT) assessment completed as planned; cleared to treat more patients with one additional patient already treated
- Initial efficacy data pending for another 23 patients in Cohort 2 and 8 patients in Cohort 3; submissions to more medical conferences in 2026 are planned, as well as regulatory engagement